Monday, April 20, 2026
← Back to archivePolicy
Policy•Fierce Biotech•Apr 20, 2026
Trump orders FDA to fast-track reviews of psychedelic drugs after lobbying by podcaster
background ▾
- •Executive order mandates FDA priority review vouchers for psychedelic drugs with Breakthrough Therapy designation, with three serotonin 2a agonists identified for priority treatment—representing a major policy shift toward psychedelic drug development.
- •Compass Pathways' COMP360 (synthetic psilocybin) positioned for accelerated review with rolling submission on track for Q4 completion; Definium Therapeutics' LSD formulation phase 3 data anticipated this year.
- •Watch for: FDA announcement of which companies receive the three vouchers, final DEA/FDA guidance on investigational psychedelic access pathway, and timing of Compass's BLA submission and potential approval.
Compass PathwaysDefinium TherapeuticsCOMP360psilocybinLSD
→ Read original articlePolicy•Fierce Biotech•Apr 19, 2026
FDA celebrates progress to end animal testing but experts warn there’s still a long way to go
background ▾
- •FDA achieved 12-month roadmap goals and aims to make animal testing the exception by 2028-2030, with concrete tools and guidance now in place (NAM database, AI qualification, monoclonal antibody guidance)
- •Industry experts counter that NAMs and animal models are complementary surrogates rather than one being superior, and that clinical trial success rates (9.6%) are comparable to animal study rates, undermining the FDA's 90% failure statistic
- •Next phase: FDA plans to expand NAM validation for critical endpoints, track animal use changes, and promote cultural shift—but experts warn this is evolutionary not revolutionary, requiring years of validation before meaningful replacement of animal testing
Charles River Laboratories
→ Read original articlePolicy•Fierce Biotech•Apr 18, 2026
AACR: FDA vet Pazdur bemoans state of agency, warns of political influence and ‘sense of anxiety’
background ▾
- •The FDA's April 1, 2025 reduction in force was chaotic and poorly managed, with staff unable to determine who was laid off or why; the agency has not adequately addressed the aftermath or restructuring plan
- •Political influence over drug approvals has increased, with the regulator noting direct pressure from leadership on approval decisions—a practice he states did not occur in prior administrations
- •The FDA has reduced reliance on external advisory committees, citing statements from current administration leadership that they 'don't believe in advisory committees,' undermining scientific rigor and public transparency
FDA
→ Read original articlePolicy•Fierce Biotech•Apr 17, 2026
Chutes & Ladders—Metsera acquisition architect swings to Structure
background ▾
- •Matthew Lang brings M&A and regulatory experience to Structure Therapeutics ahead of phase 3 advancement of oral GLP-1 candidate aleniglipron, which showed 16% weight loss in phase 2
Structure TherapeuticsMetseraPfizeraleniglipronMyfembreeOrgovyx
→ Read original articlePolicy•STAT News•Apr 18, 2026
How Trump is pushing psychedelics reform through the health agencies
background ▾
- •FDA will award three priority review vouchers to serotonin 2a agonists and expedite psychedelic drug approvals, with FDA decisions expected summer 2025
- •DEA and DOJ will initiate rescheduling reviews of psychedelics after successful Phase 3 trials, with approved drugs undergoing 'very quick' rescheduling
- •Right-to-try access enabled for psychedelics outside standard regulatory pathways; $50 million in federal funding allocated to state psychedelic programs; watch for actual rescheduling actions and Phase 3 trial timelines
IbogaineSerotonin 2a agonists
→ Read original articleMarket Access
Market Access•Fierce Biotech•Apr 17, 2026
UCB pays $650M+ for Neurona, marking 'strategic expansion' into regenerative medicine
background ▾
- •UCB's $650M+ acquisition of Neurona signals commitment to regenerative medicine and positions the company to potentially establish a novel regenerative approach in drug-resistant epilepsy alongside its existing portfolio (Fintepla and others)
- •NRTX-1001's mechanism—a single-dose stem cell therapy designed to repair neural networks via GABA restoration—could offer durable benefit in mesial temporal lobe epilepsy if clinical data support the approach through phase II
- •Monitor phase I/II trial progress for NRTX-1001; regulatory and clinical success will determine whether UCB's $1B+ total investment (including milestones) yields a meaningful commercial asset or serves primarily as a platform proof-of-concept for regenerative neurology approaches
UCBNeurona TherapeuticsNRTX-1001
→ Read original articleMarket Access•Fierce Biotech•Apr 20, 2026
How WuXi AppTec’s Integrated Platform Is Helping Therapies Move Faster from Discovery to Patients
background ▾
- •WuXi AppTec positions integrated CRDMO services as strategic differentiator in addressing rising complexity of emerging modalities and compressed development timelines
WuXi AppTec
→ Read original articleMarket Access•Pharmaceutical Technology•Apr 17, 2026
Aligos and Xiamen Amoytop sign deal for HBV therapy
background ▾
- •Pevifoscorvir sodium, a potentially first-in-class CAM-E for chronic HBV, achieves significant geographic expansion through major Asian licensing deal valued at $445 million total consideration
- •Phase II B-SUPREME interim data expected H2 2026 will be critical catalyst for both partners' valuations and advancement strategy
- •Deal validates Aligos's pipeline asset and reduces financial burn while Amoytop gains foothold in HBV market alongside existing PEGBING therapy
Aligos TherapeuticsXiamen Amoytop Biotechpevifoscorvir sodiumtenofovir disoproxil fumarate
→ Read original articleMarket Access•Fierce Pharma•Apr 20, 2026
Fierce Pharma Asia—Astellas’ stem cell therapy rethink; GSK’s bullish ADC plan; Daiichi’s OTC sale
background ▾
- •Daiichi Sankyo's $1.55 billion consumer health divestiture signals strategic exit from OTC market to concentrate on higher-margin specialty pharmaceuticals.
- •GSK's multi-phase 3 ADC expansion via Hansoh partnership indicates confidence in ADC platform but faces competition from established players in this crowded modality.
- •Astellas' stem cell therapy site closure suggests challenges in commercializing regenerative medicine or reallocation of R&D resources.
Astellas PharmaGlaxoSmithKlineHansoh Pharma
→ Read original articleMarket Access•Pharmaceutical Technology•Apr 20, 2026
Magazine: Digital twins become the new battleground for CDMOs
background ▾
- •CDMOs are adopting digital twin and knowledge-graph technologies as a competitive differentiator in manufacturing complex biologics and gene therapies
CellSave Arabia
→ Read original articleClinical Trials
Clinical Trials•Fierce Pharma•Apr 20, 2026
'Absent or trivial' effects: Anti-amyloid Alzheimer's drugs called into question once again
background ▾
- •Independent researchers are challenging the clinical meaningfulness of anti-amyloid drug efficacy, despite some FDA approvals, potentially undermining the commercial viability and clinical adoption of this drug class.
- •The skepticism reflects fundamental scientific uncertainty about whether slowing amyloid pathology translates to clinically meaningful patient benefit, complicating future development and market access strategies.
- •Monitor FDA labeling updates, payer coverage decisions, and upcoming anti-amyloid trial readouts (particularly longer-term data) to assess whether this criticism gains regulatory or reimbursement traction.
Clinical Trials•Pharmaceutical Technology•Apr 17, 2026
The innovators working to make in vivo cell therapy a reality
background ▾
- •Big pharma is acquiring in vivo cell therapy developers at billion-dollar valuations with minimal clinical data, reflecting high confidence in the modality's potential but also suggesting significant execution risk
- •Early clinical data from AstraZeneca's in vivo CAR-T shows 80% objective response rate in limited myeloma cohort; next 12 months will bring more comprehensive readouts to validate the approach
- •Regulatory and technical challenges persist: FDA guidance does not clearly distinguish in vivo cell therapies from gene therapies, and manufacturing/delivery infrastructure remains under development by CDMOs and specialist suppliers
AstraZenecaEsoBiotecEli LillyKLN-1010Xynvivo
→ Read original articleClinical Trials•Fierce Biotech•Apr 20, 2026
Biomarkers are reshaping oncology trial design
background ▾
- •Biomarker-driven trial designs (basket and umbrella trials) are replacing single-mutation approaches, with examples like trastuzumab deruxtecan doubling median PFS in HER2-low breast cancer (DESTINY-Breast04: 10 vs 5 months)
- •ctDNA and multiomic profiling technologies enable real-time monitoring and adaptive decision-making, advancing toward truly individualized cancer care
- •Operational barriers including data integration complexity, trial logistics, and enrollment challenges require hybrid testing models and molecular tumor boards to overcome
Allucenttrastuzumab deruxtecanBRAF inhibitorscheckpoint inhibitors
→ Read original articleClinical Trials•Endpoints News•Apr 20, 2026
#AACR26: KRAS drugmakers take another, better swing at lung cancer
background ▾
- •Second-generation KRAS inhibitors show superior early efficacy signals compared to first-generation KRAS drugs in lung cancer, addressing a key therapeutic gap
- •Multiple companies are advancing KRAS programs, indicating competitive intensity in this high-value indication
- •Complete trial data and head-to-head comparisons with existing standards of care are needed to fully assess clinical and commercial impact
KRAS inhibitors
→ Read original articleClinical Trials•Fierce Biotech•Apr 19, 2026
AACR: Former Genentech leader engineers startup with vision for ‘smart’ cancer drugs
background ▾
- •SDL's Synthbody platform engineers ADCs with up to four arms and 6-12 binding sites, enabling single molecules to target multiple rare cancer antigens simultaneously and adapt as tumors evolve—a novel approach distinct from conventional target-centric drug design
- •Preclinical data demonstrates >80-fold potency advantage over GSK's Blenrep in relevant disease models, supporting the platform's technical viability
- •Watch for: IND filing timeline, series A fundraising announcement, and pharma partnership deals that could validate the platform's commercial potential and determine development pathway for lead candidates
Synthetic Design LabGenentechGSKBlenrep
→ Read original article